Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tranexamic acid
Drug ID BADD_D02261
Description Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent.[L31883] It was first patented in 1957[A230108] and received its initial US approval in 1986.[L31858]
Indications and Usage Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema,[L31883] cyclic heavy menstrual bleeding in premenopausal females,[L31858] and other instances of significant bleeding in the context of hyperfibrinolysis.[L31883] Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.[L31853]
Marketing Status approved
ATC Code B02AA02
DrugBank ID DB00302
KEGG ID D01136
MeSH ID D014148
PubChem ID 5526
TTD Drug ID D05HXX
NDC Product Code 51927-0022; 73309-178; 42571-189; 50268-772; 69918-301; 70771-1085; 0591-3720; 49452-7876; 51552-0513; 81999-0001; 82920-038; 70121-1398; 23155-524; 43066-008; 55150-188; 63629-8838; 67850-041; 68083-160; 71335-1981; 60505-6169; 65145-106; 0517-0960; 81284-611; 12079-2001; 62991-3131; 82920-045; 51662-1532; 63629-8599; 67457-197; 70860-400; 70860-407; 71335-1957; 81284-612; 14537-115; 65388-0156; 61990-0611; 67850-042; 38779-3211; 57218-951; 25021-415; 42571-314; 50090-5072; 63323-563; 68382-891; 72611-760; 12848-1004; 0013-1114; 69918-300; 49452-7877; 71052-166; 23155-166; 51754-0108; 62559-265; 72485-107; 38779-2794; 39822-1000
UNII 6T84R30KC1
Synonyms Tranexamic Acid | AMCHA | trans-4-(Aminomethyl)cyclohexanecarboxylic Acid | t-AMCHA | AMCA | Anvitoff | Cyklokapron | Ugurol | KABI 2161 | Spotof | Transamin | Amchafibrin | Exacyl
Chemical Information
Molecular Formula C8H15NO2
CAS Registry Number 701-54-2
SMILES C1CC(CCC1CN)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001---
Abdominal pain07.01.05.002--
Abdominal tenderness07.01.05.004---
Acute myocardial infarction02.02.02.001; 24.04.04.0010.018705%-
Acute respiratory distress syndrome10.02.01.067; 22.01.03.001; 24.03.02.0340.003117%
Acute sinusitis11.01.13.012; 22.07.03.013---
Anaemia01.03.02.001--
Anaphylactic reaction10.01.07.001; 24.06.03.0060.021822%
Anaphylactic shock10.01.07.002; 24.06.02.0040.003117%-
Anaphylactoid reaction10.01.07.003; 24.06.03.007---
Aneurysm24.02.01.001---
Angina pectoris02.02.02.002; 24.04.04.002--
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.0010.014029%-
Aortic dissection24.02.03.002---
Aphasia17.02.03.001; 19.21.01.0010.006235%
Arrhythmia02.03.02.0010.010911%-
Arterial thrombosis24.01.01.0020.009352%-
Arthralgia15.01.02.001--
Asthenia08.01.01.001---
Atrial fibrillation02.03.03.0020.029616%
Atrioventricular block02.03.01.002---
Atrioventricular block complete02.03.01.0030.004676%
Autonomic nervous system imbalance08.01.01.010; 17.05.01.011; 24.06.01.0050.003117%-
Back pain15.03.04.0050.014029%
Blindness06.02.10.003; 17.17.01.0030.003117%-
Blindness unilateral06.02.10.007; 17.17.01.0160.010911%-
Bronchospasm10.01.03.012; 22.03.01.0040.003117%
Cardiac arrest02.03.04.0010.031175%
Cardio-respiratory arrest02.03.04.002; 22.02.06.0070.003117%-
Cardiogenic shock02.05.01.003; 24.06.02.0060.009352%-
The 1th Page    1 2 3 4 5    Next   Last    Total 9 Pages